ANTIBIOTIC-ASSOCIATED DIARRHEA AND ANTIBIOTIC-ASSOCIATED COLITIS

Cover Page

Cite item

Abstract

The article presents most recent data on antibiotic-associated intestinal disorders. The author reviews epidemiology and causative microorganisms in antibiotic-induced diarrhea and pseudomembranous colitis as well as clinical variants of antibiotic-associated disorders. Diagnosis methods are decribed at length with special attention to most sensitive and informative tests. Treatment of different clinical variants of antibiotic-induced disorders is discussed in detail.

About the authors

E. A. Belousova

Moscow Regional Research and Clinical Institute (MONIKI); 61/2 Shchepkina ul., Moscow, 129110, Russian Federation

Author for correspondence.
Email: eabelous@yandex.ru

MD, PhD, Professor, Head of the Department of Gastroenterology and Hepatology, Head of the Chair of Gastroenterology, the Faculty of Postgraduate Medical Education, MONIKI; Principal Gastroenterologist of the Moscow Region

Russian Federation

References

  1. Шевяков МА. Антибиотикассоциированная диарея и кандидоз кишечника: возможности лечения и профилактики. Антибиотики и химиотерапия. 2004;49(10):26-9. (Shevyakov MA. [Antibiotic-associated diarrhea and intestinal candidiasis: treatment and prevention]. Antibiotiki i khimioterapiya. 2004;49(10):26-9. Russian).
  2. Циммерман ЯС. Дисбиоз («дисбактериоз») кишечника и его клинические манифестные формы: антибиотикассоциированная диарея и псевдомембранозный колит. Пермь; 2005. (Tsimmerman YaS. Intestinal disbiosis and forms of its clinical manifestation: antibiotic-associated diarrhea and pseudomembranous colitis. Perm’; 2005. Russian).
  3. Rambaud JC, ButsJP, Corthier G, Flourie B, editors. Gut microflora. Digestive physiology and pathology. Paris: John Libbey Eurotext; 2006.
  4. Муконин АА, Гайдуль КВ. Антибиотикассоциированная диарея и псевдомембранозный колит как осложнения антибактериальной терапии. М.; 2004. Available from: http://www. abolmed.ru (Mukonin AA, Gaydul’ KV. Antibiotic-associated diarrhea and pseudomembranous colitis: complications of antibiotic therapy. Moscow; 2004. Available from: http://www.abolmed. ru. Russian).
  5. Парфенов АИ. Энтерология. М.: Триада-X; 2002. (Parfenov AI. Enterology. Moscow: Triada-X; 2002. Russian).
  6. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 1997;92(5):739-50.
  7. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med. 1994;330(4):257-62.
  8. Benoit R, Dorval D, Loulergue J, Bacq Y, Oliver JM, Audurier A, Metman EH. Post-antibiotic diarrheas: role of Klebsiella oxytoca. Gastroenterol Clin Biol. 1992;16(11):860-4.
  9. Белоусова ЕА. Дисбактериоз кишечника. B: Рапопорт СИ, Комаров ФИ, ред. Руководство по гастроэнтерологии. М.: ГЭОТАР-Медиа; 2010. (Belousova EA. Intestinal disbiosis. In: Rapoport SI, Komarov FI, editors. Manual of Gastroenterology. Moscow: GEOTAR-Media; 2010. Russian).
  10. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev. 2005;18(2):247-63.
  11. Осипенко МФ, Бикбулатова ЕА. Антибиотикассоциированная диарея, подходы к диагностике и лечению. Фарматека. 2007;(13):89-93. (Osipenko MF, Bikbulatova EA. [Antibioticassociated diarrhea, approaches to diagnosis and treatment]. Farmateka. 2007;(13):89-93. Russian).
  12. Ananthakrishnan AN. Detecting and treating Clostridium difficile infections in patients with inflammatory bowel disease. Gastroenterol Clin North Am. 2012;41(2):339-53.
  13. Vanpoucke H, De Baere T, Claeys G, Vaneechoutte M, Verschraegen G. Evaluation of six commercial assays for the rapid detection of Clostridium difficile toxin and/or antigen in stool specimens. Clin Microbiol Infect. 2001;7(2):55-64.
  14. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431-55.
  15. Scarpignato C, editor. Rifaximin: a poorly absorbed antibiotic. Pharmacology and clinical use. Basel: Karger; 2005.
  16. Белоусова ЕА. Sассharomyces boulardii (Энтерол) в гастроэнтерологической практике: обзор литературы. Фарматека. 2006;(12):41-5. (Belousova EA. [Sассharomyces boulardii (Enterol) in the practice of gastroenterologist: a review]. Farmateka. 2006;(12):41-5. Russian).
  17. Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, Garcia RJ, Brandmarker S, Bowen K, Borjal D, Elmer GW. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000;31(4):1012-7.
  18. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271(24):1913-8.
  19. Alander M, Satokari R, Korpela R, Saxelin M, Vilpponen-Salmela T, Mattila-Sandholm T, von Wright A. Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption. Appl Environ Microbiol. 1999;65(1):351-4.
  20. Johansson ML, Molin G, Jeppsson B, Nobaek S, Ahrné S, Bengmark S. Administration of different Lactobacillus strains in fermented oatmeal soup: in vivo colonization of human intestinal mucosa and effect on the indigenous flora. Appl Environ Microbiol. 1993;59(1):15-20.

Copyright (c) 2016 Belousova E.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies